BR9608252A - Combinação de um primeiro componente que é um inibidor de reabsorção de 5-ht e um segundo componente que é antagonista de 5-th uso da combinação processos para o tratamento de disúrbios efetivos e da depressão para a preparaç o da combinaç o e para melhoria do início de ação terapéutica formulação farmacéutica para o suo no tratamento de distúrbios efetivos e kit - Google Patents
Combinação de um primeiro componente que é um inibidor de reabsorção de 5-ht e um segundo componente que é antagonista de 5-th uso da combinação processos para o tratamento de disúrbios efetivos e da depressão para a preparaç o da combinaç o e para melhoria do início de ação terapéutica formulação farmacéutica para o suo no tratamento de distúrbios efetivos e kitInfo
- Publication number
- BR9608252A BR9608252A BR9608252A BR9608252A BR9608252A BR 9608252 A BR9608252 A BR 9608252A BR 9608252 A BR9608252 A BR 9608252A BR 9608252 A BR9608252 A BR 9608252A BR 9608252 A BR9608252 A BR 9608252A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- treatment
- component
- effective disorders
- pig
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9501567A SE9501567D0 (sv) | 1995-04-27 | 1995-04-27 | A new combination |
PCT/SE1996/000526 WO1996033710A1 (en) | 1995-04-27 | 1996-04-23 | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9608252A true BR9608252A (pt) | 1999-05-04 |
Family
ID=20398119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9608252A BR9608252A (pt) | 1995-04-27 | 1996-04-23 | Combinação de um primeiro componente que é um inibidor de reabsorção de 5-ht e um segundo componente que é antagonista de 5-th uso da combinação processos para o tratamento de disúrbios efetivos e da depressão para a preparaç o da combinaç o e para melhoria do início de ação terapéutica formulação farmacéutica para o suo no tratamento de distúrbios efetivos e kit |
Country Status (30)
Country | Link |
---|---|
US (5) | US5962514A (pt) |
EP (1) | EP0822813B1 (pt) |
JP (1) | JPH11504037A (pt) |
KR (1) | KR100419810B1 (pt) |
CN (1) | CN1102386C (pt) |
AR (1) | AR002990A1 (pt) |
AT (1) | ATE216579T1 (pt) |
BR (1) | BR9608252A (pt) |
CA (1) | CA2218181A1 (pt) |
CZ (1) | CZ335697A3 (pt) |
DE (1) | DE69620878T2 (pt) |
DK (1) | DK0822813T3 (pt) |
EE (1) | EE03553B1 (pt) |
ES (1) | ES2175089T3 (pt) |
HK (1) | HK1002853A1 (pt) |
HU (1) | HUP9801946A3 (pt) |
IL (1) | IL117988A0 (pt) |
IS (1) | IS1821B (pt) |
NO (1) | NO317057B1 (pt) |
NZ (1) | NZ306602A (pt) |
PL (1) | PL183997B1 (pt) |
PT (1) | PT822813E (pt) |
RU (1) | RU2183955C2 (pt) |
SE (1) | SE9501567D0 (pt) |
SK (1) | SK282060B6 (pt) |
TR (1) | TR199701254T1 (pt) |
TW (1) | TW458777B (pt) |
WO (1) | WO1996033710A1 (pt) |
YU (1) | YU25696A (pt) |
ZA (1) | ZA962982B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
SE9703374D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
AU4100699A (en) * | 1998-05-28 | 1999-12-13 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
SE9803158D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
SE9803157D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
SE9803155D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
SE9803156D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
US6331233B1 (en) | 2000-02-02 | 2001-12-18 | Honeywell International Inc. | Tantalum sputtering target with fine grains and uniform texture and method of manufacture |
EP1757600A2 (en) | 2000-10-13 | 2007-02-28 | NeuroSearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
US20030185754A1 (en) * | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
US7034059B2 (en) | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
US6855735B2 (en) | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
AU2003256430A1 (en) * | 2002-08-15 | 2004-03-03 | Wyeth | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION |
US20050032873A1 (en) * | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
US7695601B2 (en) * | 2006-05-09 | 2010-04-13 | The United States Of America As Represented By The Secretary Of The Army | Electrochemical test apparatus and method for its use |
US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
US20160154928A1 (en) * | 2013-07-12 | 2016-06-02 | Immuneering Corporation | Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition |
CA3049464A1 (en) | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Proline-based neuropeptide ff receptor modulators |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
US5420151A (en) * | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
US5616610A (en) * | 1989-12-22 | 1997-04-01 | Astra Aktiebolag | (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans |
SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
-
1995
- 1995-04-27 SE SE9501567A patent/SE9501567D0/xx unknown
-
1996
- 1996-04-15 TW TW085104481A patent/TW458777B/zh not_active IP Right Cessation
- 1996-04-15 ZA ZA962982A patent/ZA962982B/xx unknown
- 1996-04-21 IL IL11798896A patent/IL117988A0/xx not_active IP Right Cessation
- 1996-04-23 PL PL96323083A patent/PL183997B1/pl unknown
- 1996-04-23 CA CA002218181A patent/CA2218181A1/en not_active Abandoned
- 1996-04-23 EE EE9700245A patent/EE03553B1/xx not_active IP Right Cessation
- 1996-04-23 DE DE69620878T patent/DE69620878T2/de not_active Expired - Fee Related
- 1996-04-23 US US08/640,896 patent/US5962514A/en not_active Expired - Fee Related
- 1996-04-23 JP JP8532425A patent/JPH11504037A/ja not_active Ceased
- 1996-04-23 NZ NZ306602A patent/NZ306602A/en unknown
- 1996-04-23 BR BR9608252A patent/BR9608252A/pt not_active Application Discontinuation
- 1996-04-23 CN CN96194810A patent/CN1102386C/zh not_active Expired - Fee Related
- 1996-04-23 KR KR1019970707592A patent/KR100419810B1/ko not_active IP Right Cessation
- 1996-04-23 CZ CZ973356A patent/CZ335697A3/cs unknown
- 1996-04-23 DK DK96912370T patent/DK0822813T3/da active
- 1996-04-23 HU HU9801946A patent/HUP9801946A3/hu unknown
- 1996-04-23 EP EP96912370A patent/EP0822813B1/en not_active Expired - Lifetime
- 1996-04-23 AT AT96912370T patent/ATE216579T1/de not_active IP Right Cessation
- 1996-04-23 WO PCT/SE1996/000526 patent/WO1996033710A1/en active IP Right Grant
- 1996-04-23 TR TR97/01254T patent/TR199701254T1/xx unknown
- 1996-04-23 SK SK1429-97A patent/SK282060B6/sk unknown
- 1996-04-23 ES ES96912370T patent/ES2175089T3/es not_active Expired - Lifetime
- 1996-04-23 RU RU97119427/14A patent/RU2183955C2/ru active
- 1996-04-23 PT PT96912370T patent/PT822813E/pt unknown
- 1996-04-25 AR ARP960102323A patent/AR002990A1/es not_active Application Discontinuation
- 1996-04-26 YU YU25696A patent/YU25696A/sh unknown
-
1997
- 1997-10-09 IS IS4585A patent/IS1821B/is unknown
- 1997-10-24 NO NO19974921A patent/NO317057B1/no unknown
-
1998
- 1998-03-10 HK HK98101990A patent/HK1002853A1/xx not_active IP Right Cessation
-
1999
- 1999-07-09 US US09/349,590 patent/US6184218B1/en not_active Expired - Fee Related
- 1999-07-09 US US09/351,069 patent/US6169098B1/en not_active Expired - Fee Related
- 1999-07-09 US US09/351,070 patent/US6172105B1/en not_active Expired - Fee Related
- 1999-07-09 US US09/351,071 patent/US6184219B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9608252A (pt) | Combinação de um primeiro componente que é um inibidor de reabsorção de 5-ht e um segundo componente que é antagonista de 5-th uso da combinação processos para o tratamento de disúrbios efetivos e da depressão para a preparaç o da combinaç o e para melhoria do início de ação terapéutica formulação farmacéutica para o suo no tratamento de distúrbios efetivos e kit | |
BR9006924A (pt) | Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos | |
IL122733A0 (en) | Pharmaceutical compositions for use in the treatment of allergic asthma | |
HUP0001192A3 (en) | The use of topiramate and its derivatives for the preparation of pharmaceutical compositions treating obesity | |
BR9609467A (pt) | Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária | |
BR9709560A (pt) | Composto formulação farmacéutica uso de um compostoãe processo para tratamento de uma condição em que a inibição da trombina seja necessaria e para a preparação de um composto | |
BR9611137A (pt) | Composições e métodos para distribuição bucal de agentes farmacêuticos | |
BR9505408A (pt) | Composição terapêutica de aplicacão tópica e utilização de um antagonista de substância P | |
IT1309427B1 (it) | Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso | |
BR9710142A (pt) | Composto formulação farmacêutica utilização de um composto e processo para tratamento de uma condição em que é requerida inibição da trombina | |
BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
BR9706822A (pt) | Composição kit processo para tratamento de um distúrbio respiratório e utilização da composição do kit de formoterol de um sal ou solvato farmaceuticamente aceitável do mesmo e de budesonida | |
EP1045636A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES | |
BR9510510A (pt) | Formulação em aerossol farmacêutica uso da mesma e processos para fabricação da mesma para tratamento de um paciente carente de terapia | |
BR9508586A (pt) | Compostos processo de preparação dos mesmos uso dos mesmos processo de tratamento de uma condição clínica em um mamífero e composição farmacêutica | |
BR9406178A (pt) | Composição de amino-açucar e glicosaminoglicano para o tratamento e restauração de tecido conectivo | |
BR9703624A (pt) | Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem | |
IL114586A (en) | Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same | |
PL339541A1 (en) | Application of combinations containing non-calming antihistaminic agents and alpha-adrenergic drug in locally treating rhinitis/ophtalmitis as well as cold and cold symptoms and/or influenza | |
BRPI0308663B8 (pt) | uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas | |
HUP9902105A3 (en) | Pharmaceutical angiostatic dipeptide compositions and methods of use thereof | |
HUP9802795A3 (en) | Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence | |
BR0010531A (pt) | Composições e usos de et743 para tratamento de câncer | |
HUP9902405A3 (en) | Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |